- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01838460
Sublingual Nicotine Tablets Compared With Swedish Snus
Elevated Dose of Sublingual Nicotine Tablets Compared With Swedish Snus. Nicotine Pharmacokinetics and Subjective Effects of Single Doses.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Open, randomized, five-way cross-over. Single dose administration. The Nicorette 6 mg sublingual tablets and three strengths of SS are tested. Subjects are 18-50 years old, male/female (non-pregnant), healthy volunteer, using minimum 12 pouches of 1 g portion snus or half a can of loose snus per day. The treatments are given as single doses in randomized order. The subject keeps the sublingual tablets still under the tongue for 30 minutes.
The subject keeps the pouch(es) of snus still between the upper lip and the gum for 30 minutes. Serial blood samples are drawn before, and at regular time intervals up to 6 hours after administration.
Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment. The AUCinf area is based on plasma data corrected for background nicotine (time zero sample).
Each subject's rating of subjective effects using a Visual Analogue Scale (VAS) on a palm top computer, anchored with "not at all" to "extremely".
VAS scores will be obtained at the plasma concentrations sampling time points up to 30 minutes for:
- craving intensity
- overall "product strength" (head rush, "buzz", "hit", feeling alert)
- increased salivation
- burning sensation in the mouth and/or throat
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Skåne
-
Eslöv, Skåne, Sweden, 24123
- Carema Specialistvård, Eslöv
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Consent to participate voluntarily and sign Informed Consent Form prior to any study procedure.
- Healthy male/female, age 18 through 50 years. Female using contraceptive pill or negative pregnancy test.
- Willing and able to comply with study procedures.
- Snus user, minimum 12 pouches or half a can of loose snus per day of pouched portion snus, minimum 1 gram/portion.
- Abstinent from any form of nicotine use from 8.00 p.m.
- Fasting overnight from 11.00 p.m.
Exclusion Criteria:
- Smoker, defined as "smoking during the last 24 hours according to self report and CO in exhaled air >10 ppm at clinical visits"
- Second or third degree AV block or sick sinus syndrome; congestive heart failure classified as functional Class III or IV by the New York Heart Association; myocardial infarction within six months of baseline; a prolonged QTc interval at screen or pretreatment (defined as a QTc interval of > 450 msec for males or > 470 msec for females); other clinically significant heart conditions which would negatively impact on the subject completing the study.
- Subjects with clinically significant liver disease which may prevent the subject from completing the study and/or an elevation in total bilirubin, alkaline phosphatase, LDH, ASAT, or ALAT of > 3 times the upper limit of the laboratory reference interval.
- Subjects with clinically significant renal disease which may prevent the subject from completing the study and/or an elevation in serum creatinine of > 1.5 times the laboratory reference.
- Surgery within 6 months of the Baseline visit that, in the opinion of the investigator, could negatively impact on the subject's participation in the clinical study.
- Subjects who have participated in other drug studies within 30 days prior to enrolment.
- Subjects with any surgical or medical condition, which, in the judgment of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug.
- Subjects who are using drugs capable of inducing hepatic enzyme metabolism within the previous 30 days (or 5 half lives of inducing agent, whichever is longer) of enrolment in this study.
- Subjects with a medical history of seizures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 6 mg dose of sublingual nicotine tablets
6 mg dose of sublingual nicotine tablets, single dose.
|
6 mg = 3 tablets
Other Names:
|
ACTIVE_COMPARATOR: PSWM 0.5 g (16 mg nicotine/g)
Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
|
Swedish type moist snuff
Other Names:
|
ACTIVE_COMPARATOR: PSWL 1.0 g (8 mg nicotine /g)
Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
|
Swedish type moist snuff
Other Names:
|
ACTIVE_COMPARATOR: PSWL 1.0 g (16 mg nicotine /g)
Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
|
Swedish type moist snuff
Other Names:
|
ACTIVE_COMPARATOR: PSWL (8 mg nicotine /g) 2x1.0 g
Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
|
Swedish type moist snuff
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCinf
Time Frame: 6 hours
|
6 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
craving intensity
Time Frame: 6 hours
|
6 hours
|
|
head rush
Time Frame: 6 hours
|
overall "product strength" (head rush, "buzz", "hit", feeling alert
|
6 hours
|
burning sensation
Time Frame: 6 hours
|
burning sensation in the mouth and/or throat
|
6 hours
|
increased salivation
Time Frame: 6 hours
|
6 hours
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SM WS 12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on sublingual nicotine tablets
-
University Hospital of CologneCompletedAllergic Rhinitis
-
National Institute on Drug Dependence, ChinaBronx VA Medical CenterCompleted
-
Beijing Tiantan HospitalNeuroDawn Pharmaceutical Co., Ltd.RecruitingAcute Ischemic Stroke | Large Vessel Occlusion | ReperfusionChina
-
University Hospital, Gentofte, CopenhagenTerminated
-
Peking University Third HospitalCompleted
-
Titan PharmaceuticalsCompleted
-
Tonix Pharmaceuticals, Inc.Terminated
-
Stallergenes GreerCompletedAsthma | House Dust Mite AllergyFrance, Germany, Poland
-
Imperial College LondonALK-Abelló A/SUnknownRhinitis, Allergic, SeasonalUnited Kingdom
-
Tonix Pharmaceuticals, Inc.CompletedFibromyalgiaUnited States